Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis | Dalia Omran

Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis

Citation:: El Kassas, M., N. Abdeen, D. Omran, M. Alboraie, M. Salaheldine, M. Eltabbakhe, R. Farghaly, M. Emadeldeen, shimaa afify, and A. Sweedy, "Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis", European Journal of Gastroenterology & Hepatology, vol. 33, issue 1S Suppl 1, pp. e877-e882., 2021.